An evaluation of Ibrutinib for the treatment of Waldenstrom macroglobulinaemia
- 30 June 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Expert Opinion on Pharmacotherapy
- Vol. 21 (13), 1555-1564
- https://doi.org/10.1080/14656566.2020.1770727
Abstract
Waldenstrom Macroglobulinaemia (WM) is a heterogenous condition which poses a challenge to manage. Novel therapies such as Ibrutinib have been shown to be efficacious in treating WM. The landscape of Ibrutinib’s role in treating WM is everchanging with new discoveries in disease genomics and evolution together as well as through new findings in clinical trials. A systematic literature review was carried out using two databases ‘Medline’ and ‘Embase’ from 2009 to July 2019. Keywords used included ‘Ibrutinib,’ ‘Waldenstrom Macroglobulinaemia,’ and ‘lymphoma.’ There were four major clinical trials identified primarily describing outcomes of Ibrutinib in managing WM which this paper evaluates in detail. The authors present evidence of the role of Ibrutinib in the management of specific complications associated with WM. They also explore the recently discovered genomics of the disease affecting response to therapy. The evidence for the use of Ibrutinib as a treatment option for relapsed/refractory WM is compelling in MYD88 mutated WM with the response and survival rates potentially better than conventional salvage chemoimmunotherapy. There is also a case for it to be used in the frontline setting in patients unfit for conventional frontline chemoimmunotherapy.Keywords
This publication has 73 references indexed in Scilit:
- MYD88 L265P mutation in Waldenstrom macroglobulinemiaBlood, 2013
- Apixaban versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2011
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancyProceedings of the National Academy of Sciences of the United States of America, 2010
- Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström MacroglobulinemiaJournal of Clinical Oncology, 2010
- Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström MacroglobulinemiaJournal of Clinical Oncology, 2010
- Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180Journal of Clinical Oncology, 2009
- Primary Treatment of Waldenström Macroglobulinemia With Dexamethasone, Rituximab, and CyclophosphamideJournal of Clinical Oncology, 2007
- Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248Clinical Cancer Research, 2007
- Extended rituximab therapy in Waldenström's macroglobulinemiaAnnals of Oncology, 2005
- Early and Late Effects of Clopidogrel in Patients With Acute Coronary SyndromesJournal of the American College of Cardiology, 2003